Kidney International Reports (Apr 2021)
POS-284 CARDIOVASCULAR OUTCOMES AND EXPLORATORY ANALYSES BY ACHIEVED HB LEVELS IN POOLED PHASE 3 TRIALS OF ROXADUSTAT IN DIALYSIS-DEPENDENT PATIENTS WITH ANEMIA OF CHRONIC KIDNEY DISEASE
- R. Provenzano,
- S. Fishbane,
- P. Pergola,
- L. Szczech,
- R. Leong,
- K. Saikali,
- M. Zhong,
- T. Lee,
- M. Houser,
- D. Little,
- L. Frison,
- J. Houghton,
- K.H.P. Yu
Affiliations
- R. Provenzano
- Wayne State University, School of Medicine, Detroit, United States
- S. Fishbane
- Northwell Health, Division of Kidney Disease and Hypertension, Great Neck, United States
- P. Pergola
- Renal Associates, Renal Associates, San Antonio, United States
- L. Szczech
- FibroGen- Inc., Clinical Development, San Francisco, United States
- R. Leong
- FibroGen- Inc., Clinical Development, San Francisco, United States
- K. Saikali
- FibroGen- Inc., Clinical Development, San Francisco, United States
- M. Zhong
- FibroGen- Inc., Biometrics, San Francisco, United States
- T. Lee
- FibroGen- Inc., Biometrics, San Francisco, United States
- M. Houser
- AstraZeneca, Global Clinical Lead, Gaithersburg, United States
- D. Little
- AstraZeneca, Global Clinical Lead, Gaithersburg, United States
- L. Frison
- AstraZeneca, Statistical Science Director, Mölndal, Sweden
- J. Houghton
- AstraZeneca, Global Franchise Head, Gaithersburg, United States
- K.H.P. Yu
- FibroGen- Inc., Clinical Development, San Francisco, United States
- Journal volume & issue
-
Vol. 6,
no. 4
p. S121
